vs

Side-by-side financial comparison of Arcosa, Inc. (ACA) and Enovis CORP (ENOV). Click either name above to swap in a different company.

Arcosa, Inc. is the larger business by last-quarter revenue ($716.7M vs $548.9M, roughly 1.3× Enovis CORP). Arcosa, Inc. runs the higher net margin — 7.3% vs -104.1%, a 111.3% gap on every dollar of revenue. On growth, Arcosa, Inc. posted the faster year-over-year revenue change (7.6% vs -2.2%). Arcosa, Inc. produced more free cash flow last quarter ($55.8M vs $29.1M). Over the past eight quarters, Enovis CORP's revenue compounded faster (9.8% CAGR vs 9.4%).

Arcosa, Inc. is a provider of infrastructure-related products and solutions operating across three core segments: construction, energy, and transportation. It offers products including utility structures, construction aggregates, and transportation components, primarily serving customers across the North American market to support critical infrastructure development projects.

Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Wilmington, Delaware and is listed on the NYSE as ENOV. The company has over 5,000 employees operating at 12 sites around the world.

ACA vs ENOV — Head-to-Head

Bigger by revenue
ACA
ACA
1.3× larger
ACA
$716.7M
$548.9M
ENOV
Growing faster (revenue YoY)
ACA
ACA
+9.7% gap
ACA
7.6%
-2.2%
ENOV
Higher net margin
ACA
ACA
111.3% more per $
ACA
7.3%
-104.1%
ENOV
More free cash flow
ACA
ACA
$26.7M more FCF
ACA
$55.8M
$29.1M
ENOV
Faster 2-yr revenue CAGR
ENOV
ENOV
Annualised
ENOV
9.8%
9.4%
ACA

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ACA
ACA
ENOV
ENOV
Revenue
$716.7M
$548.9M
Net Profit
$52.1M
$-571.1M
Gross Margin
22.9%
59.9%
Operating Margin
11.0%
-101.7%
Net Margin
7.3%
-104.1%
Revenue YoY
7.6%
-2.2%
Net Profit YoY
776.6%
18.8%
EPS (diluted)
$1.06
$-9.99

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACA
ACA
ENOV
ENOV
Q4 25
$716.7M
$548.9M
Q3 25
$797.8M
$564.5M
Q2 25
$736.9M
$558.8M
Q1 25
$632.0M
Q4 24
$666.2M
$561.0M
Q3 24
$640.4M
$505.2M
Q2 24
$664.7M
$525.2M
Q1 24
$598.6M
$516.3M
Net Profit
ACA
ACA
ENOV
ENOV
Q4 25
$52.1M
$-571.1M
Q3 25
$73.0M
$-36.7M
Q2 25
$59.7M
$-56.0M
Q1 25
$23.6M
Q4 24
$-7.7M
$-703.2M
Q3 24
$16.6M
$-31.5M
Q2 24
$45.6M
$-18.6M
Q1 24
$39.2M
$-72.0M
Gross Margin
ACA
ACA
ENOV
ENOV
Q4 25
22.9%
59.9%
Q3 25
24.1%
59.3%
Q2 25
22.5%
59.5%
Q1 25
19.8%
Q4 24
19.3%
54.8%
Q3 24
21.3%
56.7%
Q2 24
20.8%
55.0%
Q1 24
18.6%
57.7%
Operating Margin
ACA
ACA
ENOV
ENOV
Q4 25
11.0%
-101.7%
Q3 25
14.1%
-3.0%
Q2 25
12.9%
-8.4%
Q1 25
8.8%
Q4 24
6.5%
-118.5%
Q3 24
5.3%
-6.3%
Q2 24
10.1%
-8.4%
Q1 24
8.9%
-6.8%
Net Margin
ACA
ACA
ENOV
ENOV
Q4 25
7.3%
-104.1%
Q3 25
9.2%
-6.5%
Q2 25
8.1%
-10.0%
Q1 25
3.7%
Q4 24
-1.2%
-125.4%
Q3 24
2.6%
-6.2%
Q2 24
6.9%
-3.5%
Q1 24
6.5%
-13.9%
EPS (diluted)
ACA
ACA
ENOV
ENOV
Q4 25
$1.06
$-9.99
Q3 25
$1.48
$-0.64
Q2 25
$1.22
$-0.98
Q1 25
$0.48
Q4 24
$-0.16
$-12.69
Q3 24
$0.34
$-0.58
Q2 24
$0.93
$-0.34
Q1 24
$0.80
$-1.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACA
ACA
ENOV
ENOV
Cash + ST InvestmentsLiquidity on hand
$214.6M
$33.6M
Total DebtLower is stronger
$1.5B
$1.4B
Stockholders' EquityBook value
$2.6B
$2.0B
Total Assets
$5.0B
$4.4B
Debt / EquityLower = less leverage
0.57×
0.67×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACA
ACA
ENOV
ENOV
Q4 25
$214.6M
$33.6M
Q3 25
$220.0M
$44.1M
Q2 25
$189.7M
$38.5M
Q1 25
$167.9M
Q4 24
$187.3M
$48.2M
Q3 24
$756.8M
$35.4M
Q2 24
$103.7M
$35.0M
Q1 24
$176.5M
$66.3M
Total Debt
ACA
ACA
ENOV
ENOV
Q4 25
$1.5B
$1.4B
Q3 25
$1.6B
$1.4B
Q2 25
$1.7B
$1.4B
Q1 25
$1.7B
Q4 24
$1.7B
$1.3B
Q3 24
$1.2B
$1.3B
Q2 24
$699.9M
$1.3B
Q1 24
$600.6M
$1.3B
Stockholders' Equity
ACA
ACA
ENOV
ENOV
Q4 25
$2.6B
$2.0B
Q3 25
$2.6B
$2.6B
Q2 25
$2.5B
$2.6B
Q1 25
$2.5B
Q4 24
$2.4B
$2.6B
Q3 24
$2.4B
$3.3B
Q2 24
$2.4B
$3.3B
Q1 24
$2.4B
$3.3B
Total Assets
ACA
ACA
ENOV
ENOV
Q4 25
$5.0B
$4.4B
Q3 25
$5.1B
$5.0B
Q2 25
$5.0B
$4.9B
Q1 25
$4.9B
Q4 24
$4.9B
$4.7B
Q3 24
$4.4B
$5.6B
Q2 24
$3.8B
$5.4B
Q1 24
$3.7B
$5.5B
Debt / Equity
ACA
ACA
ENOV
ENOV
Q4 25
0.57×
0.67×
Q3 25
0.61×
0.54×
Q2 25
0.67×
0.53×
Q1 25
0.68×
Q4 24
0.69×
0.52×
Q3 24
0.51×
0.40×
Q2 24
0.29×
0.41×
Q1 24
0.25×
0.40×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACA
ACA
ENOV
ENOV
Operating Cash FlowLast quarter
$120.0M
$82.6M
Free Cash FlowOCF − Capex
$55.8M
$29.1M
FCF MarginFCF / Revenue
7.8%
5.3%
Capex IntensityCapex / Revenue
9.0%
9.7%
Cash ConversionOCF / Net Profit
2.30×
TTM Free Cash FlowTrailing 4 quarters
$175.5M
$22.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACA
ACA
ENOV
ENOV
Q4 25
$120.0M
$82.6M
Q3 25
$160.6M
$47.8M
Q2 25
$61.2M
$-1.6M
Q1 25
$-700.0K
Q4 24
$248.2M
$88.3M
Q3 24
$135.0M
$53.6M
Q2 24
$38.3M
$7.8M
Q1 24
$80.5M
$-36.2M
Free Cash Flow
ACA
ACA
ENOV
ENOV
Q4 25
$55.8M
$29.1M
Q3 25
$121.0M
$3.4M
Q2 25
$33.4M
$-44.9M
Q1 25
$-34.7M
Q4 24
$194.9M
$35.1M
Q3 24
$100.6M
$2.4M
Q2 24
$-9.3M
$-31.6M
Q1 24
$26.1M
$-73.1M
FCF Margin
ACA
ACA
ENOV
ENOV
Q4 25
7.8%
5.3%
Q3 25
15.2%
0.6%
Q2 25
4.5%
-8.0%
Q1 25
-5.5%
Q4 24
29.3%
6.3%
Q3 24
15.7%
0.5%
Q2 24
-1.4%
-6.0%
Q1 24
4.4%
-14.2%
Capex Intensity
ACA
ACA
ENOV
ENOV
Q4 25
9.0%
9.7%
Q3 25
5.0%
7.9%
Q2 25
3.8%
7.7%
Q1 25
5.4%
Q4 24
8.0%
9.5%
Q3 24
5.4%
10.1%
Q2 24
7.2%
7.5%
Q1 24
9.1%
7.2%
Cash Conversion
ACA
ACA
ENOV
ENOV
Q4 25
2.30×
Q3 25
2.20×
Q2 25
1.03×
Q1 25
-0.03×
Q4 24
Q3 24
8.13×
Q2 24
0.84×
Q1 24
2.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACA
ACA

Engineered Structures$301.1M42%
Total Construction Materials$276.8M39%
Specialty Materials And Asphalt$110.2M15%
Construction Site Support$28.6M4%

ENOV
ENOV

Reconstructive Segment$258.0M47%
Surgical$129.0M23%
Prevention And Recovery$92.6M17%
Other Prevention And Recovery$71.4M13%

Related Comparisons